Modified TNFRI Polypeptides for Dry Eye Syndrome Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye syndrome, including artificial tears and anti-inflammatory materials, are primarily symptomatic and lack fundamental efficacy, with TNFα inhibitors like Etanercept showing limited effectiveness in improving symptoms.
Innovation Solution
Development of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptides and fragments with enhanced binding affinity to TNFα and protease resistance, specifically designed as next-generation TNFα inhibitors for topical application in treating dry eye syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional TNFα inhibitors like Etanercept are used for treating dry eye syndrome, then some anti-inflammatory effect is achieved, but therapeutic efficacy is limited and symptoms are not sufficiently improved
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of TNFRI to create variants with enhanced binding affinity to TNFα. Specific mutations at positions 37, 48, 50, and 73 optimize the interaction interface, resulting in significantly improved therapeutic efficacy compared to wild-type TNFRI and existing inhibitors like Etanercept
Solution Approach 2:
The patent creates composite structures by combining the modified TNFRI polypeptide chain with a Fc region from human IgG1, forming a fusion protein that exhibits both high TNFα binding affinity and extended serum half-life, thereby achieving superior and sustained therapeutic effects
2Ease of operation
If artificial tears and conventional anti-inflammatory materials are used, then symptomatic relief is provided, but fundamental treatment of the underlying inflammation is insufficient
Solution Approach 1:
The modified TNFRI acts as an intermediary that specifically binds to and neutralizes TNFα, the key mediator of inflammation in dry eye syndrome. By targeting this specific cytokine with high affinity, the treatment addresses the fundamental inflammatory pathway rather than merely providing symptomatic relief
3Ease of manufacture
If standard TNFRI structures are used, then basic TNFα binding function is achieved, but binding affinity and protease resistance are insufficient
Solution Approach 1:
The patent systematically modifies amino acid parameters at critical positions (37, 48, 50, 73) to enhance both binding affinity and protease resistance. These parameter changes optimize the structural and functional properties of TNFRI without compromising its basic binding function
Solution Approach 2:
The patent provides beforehand cushioning by engineering protease resistance into the TNFRI structure through specific amino acid substitutions. This pre-protection against proteolytic degradation ensures the therapeutic protein remains stable and active in the physiological environment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified TNFRI variants demonstrate significant clinical effects in treating dry eye syndrome by reducing inflammation and improving tear breakup time and corneal staining, outperforming traditional TNFα inhibitors such as Etanercept in animal models.
Implementation Method 1
enhanced binding affinity to TNFα
Data Source
AI summary
The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNFα neutralizing activity, and inhibits TNFα activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome.